

## Claims

1. An isolated polynucleotide comprising a member selected from the group consisting of:
- 5 (a) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:2;
- (b) a polynucleotide encoding a mature polypeptide having the amino acid sequence expressed by the cDNA contained in CGMCC Deposit NO.0392;
- 10 (c) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:4;
- (d) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:6;
- 15 (e) a polynucleotide encoding the polypeptide as set forth in SEQ ID NO:8;
- (f) a naturally occurring variant of the polynucleotide of (a), (b), (c), (d) or (e);
- (g) a polynucleotide capable of hybridizing to the polynucleotide of (a) or (b); and
- 20 (h) a polynucleotide which is at least 85% identical to the polynucleotide of (a) or (b).
2. The polynucleotide of Claim 1 wherein the polynucleotide is cDNA.
- 25 3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 1 wherein the polynucleotide is genomic DNA.
- 30 5. The polynucleotide of Claim 1 having the sequence as set forth in SEQ ID NO:1.
6. The polynucleotide of Claim 1 having the sequence as set forth in SEQ ID NO:3.
- 35 7. The polynucleotide of Claim 1 having the sequence as set forth in SEQ ID NO:5.

8. The polynucleotide of Claim 1 having the sequence as set forth in SEQ ID NO:7.
9. The polynucleotide of Claim 2 encoding the polypeptide as set forth in  
5 SEQ ID NO:2.
10. The polynucleotide of Claim 2 encoding a mature polypeptide having the amino acid sequence expressed by the DNA contained in CGMCC Deposit NO.0392.
11. The polynucleotide of Claim 2 encoding the polypeptide as set forth in  
10 SEQ ID NO:4.
12. The polynucleotide of Claim 2 encoding the polypeptide as set forth in  
15 SEQ ID NO:6.
13. The polynucleotide of Claim 2 encoding the polypeptide as set forth in  
SEQ ID NO:8.
14. A vector containing the cDNA of Claim 2.
15. A host cell transformed, transduced or transfected with the vector of Claim  
14.
16. A method of producing a chemokine-like factor polypeptide comprising  
25 introducing a vector of claim 14 into a host cell, and expressing from the host cell or extracellular media the polypeptide encoded by said cDNA.
17. A polypeptide comprising a member selected from the group consisting of:
- (a) a polypeptide having the deduced amino acid sequence of SEQ ID  
30 NO:2;
- (b) a polypeptide having the amino acid sequence encoded by the cDNA of CGMCC deposit NO.0392;
- (c) a polypeptide having the deduced amino acid sequence of SEQ ID  
35 NO:4;
- (d) a polypeptide having the deduced amino acid sequence of SEQ ID  
NO:6;

- (e) a polypeptide having the deduced amino acid sequence of SEQ ID NO:8; and
- (f) naturally occurring variants, analogs and derivatives of the polypeptides of (a), (b), (c), (d) and (e).

5

18. The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:2.

19. The polypeptide of claim 17 having the amino acid sequence encoded by  
10 the cDNA of CGMCC deposit NO.0392.

20. The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:4.

15 21. The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:6.

22. The polypeptide of claim 17 having the amino acid sequence of SEQ ID NO:8.

20

23. An antibody of the polypeptide of claim 17.

24. A compound which inhibits activation of the polypeptide of claim 17.

25 25. A method of using the CKLF1 polypeptide of claim 17 in the preparation of immunological adjuvants which can improve the curative effect of a DNA vaccine or a DNA drug.

26. A method for the treatment of a patient having need of the CKLF  
30 polypeptide comprising administering to said patient a therapeutically effective amount of the polypeptide of claim 17.

27. The method of Claim 26 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide  
35 and expressing said polypeptide *in vivo*.

28. A method of diagnosing a disease or a susceptibility to a disease comprising determining a mutation in the polynucleotide of claim 1.

29. A diagnostic method comprising analyzing for the presence of the  
5 polypeptide of Claim 17 in a sample derived from a host.

30. The method of Claim 28 wherein said disease comprises inflammations, degenerative diseases, primary tumors and hematopoietic disorders.

10 31. The method of Claim 30 wherein said inflammations comprise rheumatoid arthritis and other autoimmune diseases, allergies and hyperplastic diseases.

32. The method of Claim 30 wherein said degenerative diseases comprise  
15 muscular dystrophy and hair loss.

33. The method of Claim 30 wherein said tumors are selected from the group consisting of breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer and prostate cancer.

20

25

30

35